Literature DB >> 9462442

In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole.

V G Loo1, C A Fallone, E De Souza, J Lavallée, A N Barkun.   

Abstract

The in-vitro activities of omeprazole and three antimicrobial agents against 89 clinical isolates of Helicobacter pylori from a population with duodenal ulcer disease were determined by an agar dilution method. Resistance rates were 20% for metronidazole (MIC > 8 mg/L), 1% for clarithromycin (MIC > 2 mg/L) and zero for ampicillin (MIC > 8 mg/L). Omeprazole was relatively active against H. pylori in vitro (MIC < or = 8 mg/L).

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9462442     DOI： 10.1093/jac/40.6.881

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  15 in total

1.  Clarithromycin resistance in Helicobacter pylori and its clinical relevance.

Authors:  Hua-Xiang Xia; Xue-Gong Fan; Nicholas J Talley
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

2.  Antibiotic susceptibility of Helicobacter pylori clinical isolates: comparative evaluation of disk-diffusion and E-test methods.

Authors:  K K Mishra; S Srivastava; A Garg; A Ayyagari
Journal:  Curr Microbiol       Date:  2006-09-12       Impact factor: 2.188

3.  High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children.

Authors:  N Kalach; M Bergeret; P H Benhamou; C Dupont; J Raymond
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

4.  Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection.

Authors:  Michelle M Nerandzic; Michael J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2009-08-10       Impact factor: 5.191

5.  Evaluation of a selective transport medium for gastric biopsy specimens to be cultured for Helicobacter pylori.

Authors:  L K Siu; W K Leung; A F Cheng; J Y Sung; T K Ling; J M Ling; E K Ng; J Y Lau; S C Chung
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

Review 6.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

7.  In vitro antimicrobial susceptibility testing of Helicobacter felis, H. bizzozeronii, and H. salomonis.

Authors:  K Van den Bulck; A Decostere; I Gruntar; M Baele; B Krt; R Ducatelle; F Haesebrouck
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

8.  Assessment of metronidazole susceptibility in Helicobacter pylori: statistical validation and error rate analysis of breakpoints determined by the disk diffusion test.

Authors:  S Chaves; M Gadanho; R Tenreiro; J Cabrita
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

9.  Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada.

Authors:  Carlo A Fallone; Alan N Barkun; Andrew Szilagyi; Karl M Herba; Maida Sewitch; Myriam Martel; Stefanie S Fallone
Journal:  Can J Gastroenterol       Date:  2013-07       Impact factor: 3.522

10.  Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice.

Authors:  Tahir Shaikh; Carlo A Fallone
Journal:  Can J Gastroenterol Hepatol       Date:  2016-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.